Two Challenge and Rechallenge Episodes of Chloroquine-Induced Psychotic Mania in a Patient with Rheumatoid Arthritis

Abstract

Chloroquine, an anti-malarial drug, is also used in the treatment of rheumatoid arthritis. It has been known for decades that chloroquine could cause psychiatric side effects; however, reports are scarce. This report concerns a rare case of 2 challenge and re-challenge episodes of mania during chloroquine treatment of rheumatoid arthritis. Some hypothetical pathophysiological mechanisms that may lead to these adverse effects are discussed.

Zusammenfassung

Das Antimalarikum Chloroquin wird auch in der Therapie der rheumatoiden Arthritis angewendet. Seit Jahrzehnten sind seine psychiatrischen Nebenwirkungen bekannt, wurden aber nur selten dokumentiert. Es wird über einen seltenen Fall bei einem Patienten mit rheumatoider Arthritis während der Cloroquinbehandlung berichtet. Es wurden 2 Episoden psychotischer Manie beobachtet und ein re-induzierter Manieausbruch ausgelöst. Über einige hypothetische pathophysiologische Mechanismen, die zu dieser Nebenwirkung führen wird diskutiert.

Key words

chloroquine - rheumatoid arthritis - psychotic mania

Schlüsselwörter

Chloroquin - rheumatoide Arthritis - psychotische Manie

• References

• 1 Taylor WRJ, White NJ. Antimalarial drug toxicity. A review. Drug Saf 2004; 27: 25-61
• 2 Telgt DS, van der Ven AJ, Schimmer B et al. Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection. Ann Pharmacother 2005; 39: 551-554
• 3 Sahoo S, Kumar M, Sinha VK. Chloroquine-induced recurrent psychosis. Am J Ther 2007; 14: 406-407
• 4 Bhatia MS. Chloroquine-induced recurrent psychosis. Indian J Med Sci 1996; 50: 302-304
• 5 Gulec G, Yenilmez C, Ayranci U. Sulfasalazine plus chloroquine-induced mood disorder in a patient with rheumatoid arthritis. Iran J Med Sci 2009; 34: 72-75
• 6 Lysack JT, Lysack CL, Kvern BL. A severe adverse reaction to mefloquine and chloroquine prophylaxis. Aust Fam Physician 1998; 27: 1119-1120
• 7 Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis, or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27: 203-213
• 8 Yelmo S, Morera-Fumero AL, Henry M et al. Mania associated with mefloquine prophylaxis. J Clin Psychopharmacol 2010; 30: 339-341
• 9 Brumbaugh M, Price P, Fagan N et al. Psychotic mania associated with mefloquine in a bipolar patient. South Med J 2008; 101: 550-551
• 10 Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996; 31: 257-274
• 11 Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodaquine. Clinical implications. Clin Pharmacokinet 1996; 30: 263-299
• 12 AlKadi HO. Antimalarial drug toxicity: a review. Chemotherapy 2007; 53: 385-391
• 13 Tomé AM, Filipe A. Quinolones: review of psychiatric and neurologic adverse reactions. Drug Saf 2011; 34: 465-488
• 14 Hirata Y, Yamamamoto H, Atta MS et al. Chloroquine inhibits glutamate-induced death of neuronal cell line by reducing reactive oxygen species through sigma-1 receptor. J Neurochem 2011; 119: 839-847
• 15 Kim EL, Wüstenberg R, Rübsam A et al. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol 2010; 12: 389-400
• 16 Koprivica V, Regardie K, Wolff C et al. Aripiprazole protects cortical neurons from glutamate toxicity. Eur J Pharmacol 2011; 651: 73-76
• 17 Pivtoraiko VN, Stone SL, Roth KA et al. Oxidative stress and autophagy in the regulation of lysosome-dependent neuron death. Antioxid Redox Signal 2009; 11: 481-496
• 18 Van Gool WA, Weinstein HC, Scheltens P et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo controlled study. Lancet 2001; 358: 455-460